Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Testa Hurwitz & Thibeault LLP

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

ChEMBL

2

FDA UNII

2

NCI_THESAURUS

2

PUBCHEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TIGAPOTIDE

1WZ6S45S94

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Tigapotide (also known as PCK3145) is a synthetic peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid. PSP94 expression in the pro...

state is downregulated in patients with advanced prostate cancer and believed to be a survival mechanism for the cancer cells. Tigapotide can exert anticancer activity not only on prostate but also on breast and colon cancer cells, possibly through laminin receptor-mediated activation of MEK and ERK1/2 phosphorylation. However, the exact molecular mechanisms of action of Tigapotide against prostate cancer tumor growth and metastasis, and tumor-associated angiogenesis remain poorly understood. In preclinical trials, Tigapotide shows potent anticancer activity and reduces prostate cancer growth in PC3 xenograft mouse model and the Dunning rat R-3327 MLL model. Phase II a clinical trial results with Tigapotide confirmed its therapeutic safety and tolerability for metastatic hormone-refractory prostate cancer. This effect was in part correlated to a marked reduction in the high levels of plasma MMP-9, a gelatinase B enzyme involved in extracellular matrix degradation and tumor invasion, of patients receiving Tigapotide, suggesting a biological effect possibly related to control metastasis.

TIGAPOTIDE TRIFLUTATE

6227JFW01C

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Tigapotide (also known as PCK3145) is a synthetic peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid. PSP94 expression in the pro...

state is downregulated in patients with advanced prostate cancer and believed to be a survival mechanism for the cancer cells. Tigapotide can exert anticancer activity not only on prostate but also on breast and colon cancer cells, possibly through laminin receptor-mediated activation of MEK and ERK1/2 phosphorylation. However, the exact molecular mechanisms of action of Tigapotide against prostate cancer tumor growth and metastasis, and tumor-associated angiogenesis remain poorly understood. In preclinical trials, Tigapotide shows potent anticancer activity and reduces prostate cancer growth in PC3 xenograft mouse model and the Dunning rat R-3327 MLL model. Phase II a clinical trial results with Tigapotide confirmed its therapeutic safety and tolerability for metastatic hormone-refractory prostate cancer. This effect was in part correlated to a marked reduction in the high levels of plasma MMP-9, a gelatinase B enzyme involved in extracellular matrix degradation and tumor invasion, of patients receiving Tigapotide, suggesting a biological effect possibly related to control metastasis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1